In this interview with a UK-based KOL, they share insights on the prescribing landscape in the UK and provide estimates of inhaler market shares within the COPD field. The KOL engages in a comprehensive discussion regarding the potential of biologics such as Dupixent, as well as biologics in late-stage development. Furthermore, the interview covers the utilization of triple inhalers and the management of asthma-COPD overlap syndrome. 

This interview was conducted on 23 May 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.